It promotes apoptosis and differentiation in imatinib-resistant chronic granulocytic leukemia cells through induction of proteasome inhibition and caspase-dependent BCR-ABL downregulation. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.